BRIEF published on 07/23/2026 at 16:01, 1 month 3 days ago ABL Diagnostics falls below the 95% threshold Growth Strategy Stock Liquidity Majority Shareholder ABL Diagnostics Widening Of The Floating
BRIEF published on 07/23/2026 at 09:27, 1 month 3 days ago ABL Diagnostics takes over TEXCELL's activities Investment ABL Diagnostics Virology Genopole TEXCELL Takeover
PRESS RELEASE published on 07/23/2026 at 09:22, 1 month 3 days ago Inside Information / Other news releases ABL Diagnostics selected by the \u00c9vry Commercial Court to acquire TEXCELL's operations, enhancing life sciences and infectious diseases activities at Genopole Acquisition Molecular Diagnostics ABL Diagnostics Genopole TEXCELL
BRIEF published on 07/13/2026 at 08:05, 1 month 13 days ago Half-yearly review of the ABL Diagnostics Liquidity Contract in 2026 Liquidity Contract Stock Market Transactions ABL Diagnostics Half-year Review First Half Of 2026
BRIEF published on 06/18/2026 at 13:57, 2 months 8 days ago ABL Diagnostics: Growth and Outlook for 2026 INVEST SECURITIES Growth Partnerships Molecular Diagnosis Genotyping
BRIEF published on 06/18/2026 at 13:57, 2 months 8 days ago ABL Diagnostics Projects Notable Growth and Upward Potential Strategic Partnerships Revenue Increase Buy Recommendation ABL Diagnostics Growth 2026
PRESS RELEASE published on 06/18/2026 at 13:52, 2 months 8 days ago Inside Information / Other news releases ABL Diagnostics confirms growth trajectory with strong upside potential. Invest Securities raises target price to €8.7 and maintains 'Buy' recommendation INVEST SECURITIES Target Price Growth Trajectory Upside Potential ABL Diagnostics
BRIEF published on 06/12/2026 at 08:05, 2 months 14 days ago ABL Diagnostics and CDL Pharma Secure €2.7 Million Contract Clinical Program Neurodegenerative Diseases International Contract ABL Diagnostics CDL Pharma
BRIEF published on 06/12/2026 at 08:05, 2 months 14 days ago ABL Diagnostics and CDL Pharma sign a €2.7 million contract until 2031 Clinical Trials Neurodegenerative Diseases ABL Diagnostics Multi-year Contract CDL Pharma
PRESS RELEASE published on 06/12/2026 at 08:00, 2 months 14 days ago Inside Information / Other news releases ABL Diagnostics and CDL Pharma secure a multi-year international contract of up to €2.7 million through 2031. The contract involves services for neurodegenerative disease clinical programs across North America, Europe, and Asia Neurodegenerative Diseases ABL Diagnostics Multi-year Contract CDL Pharma International Clinical Program
Published on 08/27/2026 at 02:35, 2 hours 55 minutes ago Galantas Gold Reports Second Quarter 2026 Results
Published on 08/27/2026 at 02:00, 3 hours 30 minutes ago Algo Grande Copper Announces Upsizing of Private Placement
Published on 08/27/2026 at 00:05, 5 hours 25 minutes ago Kidoz Reports Record Q2 2026 Revenue, up 37%, as H1 Revenue Reaches US$6.28 Million (CAD$8.66 Million)
Published on 08/26/2026 at 23:00, 6 hours 30 minutes ago Datametrex Announces Transition to Semi-Annual Financial Reporting
Published on 08/26/2026 at 22:30, 7 hours ago AI/ML Innovations Inc. Closes First Tranche of Private Placement
Published on 08/27/2026 at 05:05, 25 minutes ago Exascend Deploys Advanced Medical-Grade Storage Solutions to Power Next-Generation Healthcare Systems
Published on 08/27/2026 at 03:00, 2 hours 30 minutes ago Hong Kong Fashion Fest presents eight flagship programmes for its third edition
Published on 08/26/2026 at 23:05, 6 hours 25 minutes ago Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta
Published on 08/26/2026 at 18:44, 10 hours 46 minutes ago AUSTRIACARD HOLDINGS AG: Press Release H1 2026 Financial Results
Published on 08/26/2026 at 18:40, 10 hours 50 minutes ago MBC GROUP REVEALS MBC GAMES STUDIO WITH DEBUT TITLE UNVEILING AT GAMESCOM
Published on 08/26/2026 at 18:02, 11 hours 28 minutes ago Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:00, 11 hours 30 minutes ago Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
Published on 08/25/2026 at 17:45, 1 day 11 hours ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 08/25/2026 at 17:45, 1 day 11 hours ago Imerys-08-2026-information-share-capital-and-voting-rights-as-of-31-July-2026
